Health
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021? – Motley Fool Australia
This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna(NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year,…
-
General23 hours agoZac Lomax released by Eels for ‘opportunities outside NRL’, fuelling speculation of R360 switch
-
General22 hours agoIslam Makhachev claims UFC welterweight belt with dominant win over Jack Della Maddalena
-
General13 hours agoAmbulance response times sluggish despite Tasmanian ramping ‘ban’ promise
-
General22 hours agoIs the Coalition up for the Net Zero fight?